AR061890A1 - Sal xinafoato del etil ester de la 1-[[5-(1s)-aminoetil)-2-[8-metoxi-2(trifluorometil)-5-quinolil]-4-oxazolil]carbonil]-(4r)-[(ciclopropil-carbonil)amino]-l-prolina. - Google Patents

Sal xinafoato del etil ester de la 1-[[5-(1s)-aminoetil)-2-[8-metoxi-2(trifluorometil)-5-quinolil]-4-oxazolil]carbonil]-(4r)-[(ciclopropil-carbonil)amino]-l-prolina.

Info

Publication number
AR061890A1
AR061890A1 ARP070103086A ARP070103086A AR061890A1 AR 061890 A1 AR061890 A1 AR 061890A1 AR P070103086 A ARP070103086 A AR P070103086A AR P070103086 A ARP070103086 A AR P070103086A AR 061890 A1 AR061890 A1 AR 061890A1
Authority
AR
Argentina
Prior art keywords
carbonil
aminoetil
oxazolil
ciclopropil
quinolil
Prior art date
Application number
ARP070103086A
Other languages
English (en)
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of AR061890A1 publication Critical patent/AR061890A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

Polimorfos, procesos de síntesis de las formas polimorficas, composiciones farmacéuticas que los comprenden y sus usos para tratar enfermedades de las vías aéreas superiores e inferiores. Reivindicacion 1: El compuesto que tiene la formula estructural (1).
ARP070103086A 2006-07-11 2007-07-11 Sal xinafoato del etil ester de la 1-[[5-(1s)-aminoetil)-2-[8-metoxi-2(trifluorometil)-5-quinolil]-4-oxazolil]carbonil]-(4r)-[(ciclopropil-carbonil)amino]-l-prolina. AR061890A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US83005706P 2006-07-11 2006-07-11

Publications (1)

Publication Number Publication Date
AR061890A1 true AR061890A1 (es) 2008-10-01

Family

ID=38895717

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP070103086A AR061890A1 (es) 2006-07-11 2007-07-11 Sal xinafoato del etil ester de la 1-[[5-(1s)-aminoetil)-2-[8-metoxi-2(trifluorometil)-5-quinolil]-4-oxazolil]carbonil]-(4r)-[(ciclopropil-carbonil)amino]-l-prolina.

Country Status (22)

Country Link
US (1) US7919505B2 (es)
EP (1) EP2038277A2 (es)
JP (2) JP5097774B2 (es)
KR (1) KR20090026217A (es)
CN (1) CN101547920B (es)
AR (1) AR061890A1 (es)
AU (1) AU2007273007B2 (es)
BR (1) BRPI0712915A2 (es)
CA (1) CA2657902A1 (es)
CL (1) CL2007002020A1 (es)
CO (1) CO6190533A2 (es)
EC (1) ECSP099045A (es)
IL (1) IL196402A0 (es)
MX (1) MX2009000460A (es)
NO (1) NO20090646L (es)
NZ (1) NZ574070A (es)
PE (2) PE20080550A1 (es)
RU (1) RU2009104346A (es)
SG (1) SG173366A1 (es)
TW (1) TW200813040A (es)
WO (1) WO2008008327A2 (es)
ZA (1) ZA200900208B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2565599C (en) * 2004-05-18 2012-07-31 Schering Corporation Substituted 2-quinolyl-oxazoles useful as pde4 inhibitors
EP2385051A1 (en) * 2006-08-14 2011-11-09 Schering Corporation Process for making a substituted oxazole
CA2692781A1 (en) * 2007-07-10 2009-01-15 Schering Corporation Process for the production of substituted 5-quinolyl-oxazoles and pharmaceutically acceptable salts thereof
EP2176257A2 (en) * 2007-07-10 2010-04-21 Schering Corporation Hydrogen chloride salt of a substituted 5-oxazol-2-yl-quinoline compound and a process for the production thereof
JP5709101B2 (ja) * 2010-09-01 2015-04-30 東レ・ファインケミカル株式会社 ヒドロキシプロリン誘導体の製造法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2600644B2 (ja) 1991-08-16 1997-04-16 藤沢薬品工業株式会社 チアゾリルベンゾフラン誘導体
US5352707A (en) 1992-03-26 1994-10-04 Harbor Branch Oceanographic Institution, Inc. Method for treating airway congestion
US5270324A (en) 1992-04-10 1993-12-14 Merck Frosst Canada, Inc. Fluorinated hydroxyalkylquinoline acids as leukotriene antagonists
US5472964A (en) 1992-12-22 1995-12-05 Merck Frosst Canada, Inc. Diaryl 5,6-fused heterocyclic acids as leukotriene antagonists
CZ296163B6 (cs) 1996-05-20 2006-01-11 Karboxyamidy chinolinu jako inhibitory TNF a inhibitory PDE-IV
WO1997044322A1 (en) 1996-05-20 1997-11-27 Darwin Discovery Limited Quinoline sulfonamides as tnf inhibitors and as pde-iv inhibitors
US6069151A (en) 1996-11-06 2000-05-30 Darwin Discovery, Ltd. Quinolines and their therapeutic use
US20050017134A1 (en) 2003-07-24 2005-01-27 Hooper Patricia E. Glass and bottle holders
CA2565599C (en) * 2004-05-18 2012-07-31 Schering Corporation Substituted 2-quinolyl-oxazoles useful as pde4 inhibitors
WO2006105401A2 (en) * 2005-03-30 2006-10-05 Schering Corporation Medicaments and methods combining an anticholinergic, a corticosteroid, and a long acting beta agonist

Also Published As

Publication number Publication date
KR20090026217A (ko) 2009-03-11
JP2012214482A (ja) 2012-11-08
PE20110391A1 (es) 2011-06-22
MX2009000460A (es) 2009-01-27
US20080027101A1 (en) 2008-01-31
SG173366A1 (en) 2011-08-29
ZA200900208B (en) 2010-01-27
US7919505B2 (en) 2011-04-05
AU2007273007B2 (en) 2012-11-01
WO2008008327A2 (en) 2008-01-17
ECSP099045A (es) 2009-02-27
NO20090646L (no) 2009-04-07
IL196402A0 (en) 2009-09-22
RU2009104346A (ru) 2010-08-20
CL2007002020A1 (es) 2008-02-22
TW200813040A (en) 2008-03-16
CN101547920B (zh) 2012-06-27
WO2008008327A3 (en) 2008-03-06
EP2038277A2 (en) 2009-03-25
JP2009542811A (ja) 2009-12-03
PE20080550A1 (es) 2008-06-13
BRPI0712915A2 (pt) 2012-10-09
AU2007273007A1 (en) 2008-01-17
JP5097774B2 (ja) 2012-12-12
NZ574070A (en) 2011-12-22
CO6190533A2 (es) 2010-08-19
CN101547920A (zh) 2009-09-30
CA2657902A1 (en) 2008-01-17

Similar Documents

Publication Publication Date Title
CO2018005640A2 (es) Compuestos inhibidores de jak quinasa para el tratamiento de enfermedad respiratoria
PE20181010A1 (es) Derivados de n-[2-(1-benzilpiperidin-4-il)etil]-4-(pirazin-2-il)-piperazina-1-carboxamida y compuestos relacionados como antagonistas del receptor muscarinico 4 (m4) para tratar trastornos neurologicos
EA201992126A1 (ru) Ингибиторы jak, содержащие 4-членный гетероциклический амид
GT200800242A (es) Derivados biciclicos como inhibidores de cetp
CU20150014A7 (es) Análogos de piridazina 1,4-disustituida y métodos para el tratamiento de condiciones relacionadas con la deficiencia de smn
UY30414A1 (es) Metano sulfonatos, propano-1-sulfonatos y ciclopropan sulfonatos sustituidos con [2,3,4,8-tetrahidroimidazo-[1,5-al-pirimidin-8-il]-fenilo, composiciones farmacéuticas conteniéndolos y aplicaciones.
ECSP12011857A (es) Compuestos de dióxido de iminotiadiazina como inhibidores de bace, composiciones, y su uso
UY30498A1 (es) Nueva clase de compuestos de benzimidazolilo, sus sales, composiciones farmacéuticas conteniéndolos y aplicaciones
BR112013028430A2 (pt) composto, composição farmacêutica, método para tratar uma doença ou condição mediada por tirosina quinase do baço (syk), e, uso de uma quantidade terapeuticamente eficiente do composto
ECSP13013048A (es) Spiro-[1,3]-oxacinas y spiro-[1,4]-oxacepinas como inhibidores
SV2011003903A (es) Aminotetrahidropiranos como inhibidores de dipeptidil peptidasa iv para el tratamiento o prevencion de diabetes
EA201500298A1 (ru) Алкоксипиразолы в качестве активаторов растворимой гуанилатциклазы
DOP2006000169A (es) Inhibidores espiropiperidina de beta-secretasa para el tratamiento de la enfermedad de alzheimer
CR10250A (es) Derivados de amida y su aplicación para el tratamiento de enfermedades relacionadas con proteína-g
EA200901138A1 (ru) Производные дианилинопиримидина как ингибиторы киназы wee1, фармацевтическая композиция и применение
ECSP088876A (es) Formas de polimorfos de la (2s)-(4e)-n-metil-5-(3-isopropoxipiridin)il]-4-penten-2-amina para el tratamiento de desórdenes del sistema nervioso central
CR10138A (es) 1h indoles sustituidos por sulfonilo como ligandos para los receptores 5-hidroxitriptamina
EA201300250A1 (ru) Оксадиазольные ингибиторы продуцирования лейкотриена
AR054786A1 (es) (6-fluor-benzol(1,3) dioxolil)-morfolin-4-il-metanomas, moduladoras del receptor cb1
EA201490272A1 (ru) Новые 4-пиперидинильные соединения для применения в качестве ингибиторов танкиразы
AR093705A1 (es) Depsipeptido y sus usos
CO6480931A2 (es) Sulfonamidas heterocíclicas, usos y composiciones farmacéuticas de las mismas.
PE20180412A1 (es) Compuestos inhibidores de la senalizacion de la via de notch
UY37837A (es) Nuevos compuestos heterocíclicos como inhibidores de cdk8/19
ATE517869T1 (de) Herstellung substituierter morphinan-6-one und salzen und zwischenprodukten davon

Legal Events

Date Code Title Description
FA Abandonment or withdrawal